Display options
Cite
Shi Y, Hu Y, Hu X, et al. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015;6(6):785-91doi: 10.1111/1759-7714.12303.
Shi, Y., Hu, Y., Hu, X., Li, X., Lin, L., & Han, X. (2015). Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thoracic cancer, 6(6), 785-91. https://doi.org/10.1111/1759-7714.12303
Shi, Yuankai, et al. "Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial." Thoracic cancer vol. 6,6 (2015): 785-91. doi: https://doi.org/10.1111/1759-7714.12303
Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial. Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20. PMID: 26557919; PMCID: PMC4632933.
Copy Download .nbib Format: NLM
Share it on

Thorac Cancer. 2015 Nov;6(6):785-91. doi: 10.1111/1759-7714.12303. Epub 2015 Aug 20.

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.

Thoracic cancer

Yuankai Shi, Yi Hu, Xingsheng Hu, Xue Li, Lin Lin, Xiaohong Han

Affiliations

  1. Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, China.
  2. Department of Oncology, Chinese, General Hospital, Medical School of Chinese Beijing, China.
  3. Department of Medical Oncology, China-Japan Friendship Hospital Beijing, China.

PMID: 26557919 PMCID: PMC4632933 DOI: 10.1111/1759-7714.12303

Abstract

BACKGROUND: This study evaluated the efficacy and safety of irinotecan/cisplatin (IP) and etoposide/cisplatin (EP) in extensive-stage small cell lung cancer (ES-SCLC) and the distribution of uridine diphosphate glucuronosyltransferase (UGT1A1). The relationship between UGT1A1 genotypes and patient outcomes was also assessed.

METHOD: Patients with untreated ES-SCLC were randomly assigned to receive either IP or EP, and blood specimens were collected to test the genotypes of UGT1A1*28 and UGT1A1*6. The association of efficacy and toxicity of an IP regimen with UGT1A1 genotype was analyzed.

RESULTS: Of the 62 patients enrolled from three institutions, 30 patients were in the IP and 32 patients were in the EP arms, respectively. Disease control rates with IP and EP were 83.3% and 71.9%, respectively (P = 0.043). Median progression-free survival for IP and EP were both six months. Median overall survival for IP and EP were 18.1 and 15.8 months respectively, without significant difference. Grade 3-4 thrombocytopenia was more common with EP (18.8% vs. 6.7%; P = 0.035), while the incidence of diarrhea was higher with IP (70% vs. 15.6%; P = 0.008). The incidence of grade 1-4 late-onset diarrhea of wild-type, heterozygous, and homozygous UGT1A1*28 were 65.0%, 85.7%, and 66.7%, respectively (P = 0.037). UGT1A1*28 polymorphisms, Eastern Cooperative Oncology Group performance status, and chemotherapy cycles were essential factors affecting grade 1-4 late-onset diarrhea in logistic regression analysis.

CONCLUSIONS: The efficacy of the IP regimen was similar to the EP regimen for untreated ES-SCLC. UGT1A1 polymorphisms were associated with late-onset diarrhea; however, there was no influence on efficacy.

Keywords: Cisplatin; UGT1A1; etoposide; extensive-stage small cell lung cancer; irinotecan

References

  1. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  2. J Thorac Oncol. 2010 Jun;5(6):867-73 - PubMed
  3. Pharmacogenomics. 2009 May;10 (5):733-9 - PubMed
  4. J Clin Oncol. 2006 May 20;24(15):2237-44 - PubMed
  5. Lung Cancer. 2009 Jan;63(1):115-20 - PubMed
  6. Eur J Cancer. 2010 Jul;46(10 ):1856-65 - PubMed
  7. J Clin Oncol. 2009 May 20;27(15):2530-5 - PubMed
  8. Pharmacogenetics. 1998 Aug;8(4):357-60 - PubMed
  9. Pharmacogenet Genomics. 2005 Oct;15(10):677-85 - PubMed
  10. PLoS One. 2013;8(3):e58489 - PubMed
  11. Chin J Cancer. 2014 Aug;33(8):402-5 - PubMed
  12. Cancer. 2008 May 1;112(9):1932-40 - PubMed
  13. Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60 - PubMed
  14. N Engl J Med. 2002 Jan 10;346(2):85-91 - PubMed
  15. Pharmacogenomics J. 2014 Oct;14 (5):424-31 - PubMed
  16. Br J Cancer. 2008 Jul 22;99(2):275-82 - PubMed
  17. J Clin Oncol. 2006 May 1;24(13):2038-43 - PubMed
  18. Clin Lung Cancer. 2011 Mar;12(2):87-93 - PubMed
  19. Cancer Sci. 2007 Sep;98 (9):1461-7 - PubMed
  20. Hematol Oncol Clin North Am. 2004 Apr;18(2):373-85 - PubMed
  21. J Thorac Oncol. 2010 Dec;5(12):1986-93 - PubMed
  22. Genet Med. 2009 Jan;11(1):21-34 - PubMed
  23. J Natl Cancer Inst. 2007 Sep 5;99(17 ):1290-5 - PubMed
  24. Genet Med. 2009 Jan;11(1):15-20 - PubMed
  25. Cancer. 2010 Dec 15;116(24):5710-5 - PubMed

Publication Types